LEMAITRE VASCULAR INC Files DEF 14A for Fiscal Year Ending 2023

TL;DR

<b>Lemaitre Vascular Inc. has filed its Definitive Proxy Statement (DEF 14A) for the fiscal year ending December 31, 2023.</b>

AI Summary

LEMAITRE VASCULAR INC (LMAT) filed a Proxy Statement (DEF 14A) with the SEC on April 16, 2024. Filing is a Definitive Proxy Statement (DEF 14A) for Lemaitre Vascular Inc. The report covers the fiscal year ending December 31, 2023. The filing was made on April 16, 2024. The company's principal executive offices are located at 63 Second Avenue, Burlington, MA 01803. The SIC code for the company is 3841 (Surgical & Medical Instruments & Apparatus).

Why It Matters

For investors and stakeholders tracking LEMAITRE VASCULAR INC, this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation, board nominations, and other corporate governance matters before the annual meeting. Shareholders can use this information to make informed voting decisions on proposals presented by the company and any shareholder proposals.

Risk Assessment

Risk Level: low — LEMAITRE VASCULAR INC shows low risk based on this filing. The filing is a routine DEF 14A, indicating no immediate material changes or urgent concerns are being disclosed beyond standard corporate governance information.

Analyst Insight

Review the proxy statement for details on executive compensation, board member elections, and any shareholder proposals to inform voting decisions.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed Period of Report)
• 2024-04-16 — Filing Date (As of Date)
• DEF 14A — Form Type (Filing Values)
• 001-33092 — SEC File Number (Filing Values)

Key Players & Entities

• LEMAITRE VASCULAR INC (company) — Filer
• 0001158895 (company) — Central Index Key
• 3841 (company) — Standard Industrial Classification
• 63 Second Avenue (company) — Business Address Street 1
• Burlington (company) — Business Address City
• MA (company) — Business Address State
• 01803 (company) — Business Address ZIP
• 781-221-2266 (company) — Business Phone

FAQ

Industry Context

Lemaitre Vascular Inc. operates in the medical devices sector, specifically focusing on surgical instruments and apparatus for vascular conditions.

Regulatory Implications

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934, mandating public companies to provide detailed information to shareholders regarding corporate governance and voting matters.

What Investors Should Do

1. Review executive compensation details and rationale.
2. Examine director nominations and qualifications.
3. Understand all shareholder proposals and management's recommendations.

Key Dates

• 2024-04-16: Filing Date — Submission of the DEF 14A filing.
• 2023-12-31: Fiscal Year End — Period covered by the financial information in the proxy statement.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure for proxy voting, not a report of new financial results or material events.

Filing Documents

• lmat20240408_def14a.htm (DEF 14A) — 1438KB
• grph01.jpg (GRAPHIC) — 42KB
• grph02.jpg (GRAPHIC) — 41KB
• grph03.jpg (GRAPHIC) — 38KB
• grph04.jpg (GRAPHIC) — 34KB
• logo01.jpg (GRAPHIC) — 4KB
• pxyb01.jpg (GRAPHIC) — 148KB
• pxyb02.jpg (GRAPHIC) — 178KB
• pxyc01.jpg (GRAPHIC) — 199KB
• pxyc02.jpg (GRAPHIC) — 197KB
• sig01.jpg (GRAPHIC) — 8KB
• sig02.jpg (GRAPHIC) — 4KB
• 0001437749-24-012147.txt (&nbsp;) — 4589KB
• lmat-20231231.xsd (EX-101.SCH) — 8KB
• lmat-20231231_def.xml (EX-101.DEF) — 10KB
• lmat-20231231_lab.xml (EX-101.LAB) — 21KB
• lmat-20231231_pre.xml (EX-101.PRE) — 10KB
• lmat20240408_def14a_htm.xml (XML) — 218KB

From the Filing

lmat20240408_def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 LeMaitre Vascular, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. LeMaitre Vascular, Inc. 63 Second Avenue Burlington, Massachusetts 01803 April 16, 2024 Dear Fellow Stockholder: You are cordially invited to attend the 2024 Annual Meeting of Stockholders of LeMaitre Vascular, Inc., which will be held at 10:00 a.m. on Monday, June 3, 2024, at our offices at 32 Third Avenue, Burlington, Massachusetts 01803. This booklet includes a notice of meeting and proxy statement. The proxy statement describes the business to be conducted at the meeting and provides other information that you should know when you vote your shares. It is important that your shares be represented whether or not you attend the meeting. You can vote your shares by marking your votes on the proxy card, signing and dating it, and mailing it promptly using the envelope provided. We have provided space on the proxy card for comments. We urge you to use it to let us know your feelings about LeMaitre or to bring a particular matter to our attention. If you hold your shares through an intermediary, please feel free to write directly to us. George W. LeMaitre Chairman and Chief Executive Officer LeMaitre Vascular, Inc. 63 Second Avenue Burlington, Massachusetts 01803 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TIME AND DATE 10:00 a.m., Eastern Time, on Monday, June 3, 2024 PLACE LeMaitre Vascular, Inc. 32 Third Avenue Burlington, Massachusetts 01803 ITEMS OF BUSINESS (1) To elect three Class III directors nominated by the Board of Directors for three-year terms. (2) To conduct an advisory vote on the compensation of the Company's named executive officers. (3) To approve the Fourth Amended and Restated 2006 Stock Option and Incentive Plan. (4) To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for 2024. (5) To transact such other business as may properly come before the meeting and any adjournment or postponement thereof. RECORD DATE You can vote if you were a stockholder of record on April 5, 2024. ANNUAL REPORT Our 2023 annual report, which is not a part of the proxy solicitation material, is enclosed. PROXY VOTING Your vote is important, regardless of the number of shares you own. If you do not attend the meeting to vote in person, your vote will not be counted unless a proxy representing your shares is presented at the meeting. To ensure that your shares will be voted at the meeting, please vote by marking, signing, dating, and promptly returning the enclosed proxy card in the postage-paid envelope provided. If you do attend the meeting, you may revoke your proxy and vote by ballot. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder. By Order of the Board of Directors, Joseph P. Pellegrino Chief Financial Officer, Director and Secretary April 16, 2024 Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to be Held on June 3, 2024 This proxy statement, the notice of the annual meeting, a sample proxy card, our 2023 annual report to stockholders and directions to attend the Annual Meeting in person are available at http://www.lemaitre.com/proxy. The Board of Directors recommends that you vote FOR each of proposals one, two, three and four. LEMAITRE VASCULAR, INC. PROXY STATEMENT ANNUAL MEETING AND VOTING INFORMATION Why did I receive these proxy materials? You are receiving these proxy materials in connection with the solicitation of proxies on behalf of the Board of Directors ("Board" or "Board of Directors") of LeMaitre Vascular, Inc. ("we," "us," "our," "LeMaitre" or the "Company") for use at the Annual Meeting of Stockholders on June 3, 2024 ("Meeting"). We are sending this proxy statement to all stockholders of record as of the close of business on April 5, 2024 ("Record Date") on or about April 22, 2023. You may obtain additional

View Full Filing

View this DEF 14A filing on SEC EDGAR